A new nanomedical treatment is being developed by NanoViricides NNVC, a pharmaceutical company. It as of late refreshed the world on the situation with its hotly anticipated and presently dynamic preliminaries into its lead drug up-and-comer, NV-CoV-2.
“The Company’s lead drug candidate for the treatment of coronavirus infections, including COVID and potentially many long-term COVID cases, NV-CoV-2, has entered human clinical trials that were initiated by the Drug Sponsor, Karveer Meditech Pvt. Ltd. India, the Licensee of the Company and co-developer in India,” the company stated.
The company NanoViricides is working on cutting-edge nanomedicine treatments that use the unique ability of their nanomicelles to directly attack and destroy virus particles. The nanoviricides mimic the receptor site on the cell to which the virus binds in order to accomplish this. Since this location remains unchanged regardless of the number of variants produced, the virus is unlikely to escape the nanoviricide.
To combat COVID-19 and possibly all other human coronaviruses, the company’s drug candidate NV-CoV-2 makes use of its patented nanoviricide platform technology.
The Need for a Long-Term Coronavirus Treatment Despite the company’s frantic efforts to develop its leading drug, there is still a significant demand for safe and long-term COVID-19 and other coronavirus treatments.
It has been assessed that toward the finish of the four-year time frame from January 2020 to December 2023, the Coronavirus pandemic will have cost the American economy up to $14 trillion.
In addition, it is estimated that 65 million people still have “long COVID,” in which coronavirus symptoms persist for months after the infection has subsided clinically. The number of people diagnosed with long Covid is continuing to rise, and symptoms can range from mild to severe.
Is NV-CoV-2 Suitable for Use in Future Pandemics?
Then there are the dangers posed by additional coronaviruses and potential pandemics. According to a prediction made by the group of researchers who study diseases Metabiota, there is a chance of between 47 and 57 percent that another pandemic as severe as COVID-19 will occur within the next 25 years.
Because of this, NanoViricides considers it crucial to develop a medication that is both safe and effective for treating a wide range of patients. There are oral and injectable versions of its drug candidate NV-CoV-2 for mild cases and a solution for more severe cases. The organization is concentrating on treatment for Coronavirus for the present, yet the inventive nanomedicine might be a wide range antiviral for treating infections past Coronavirus.
Dr. Anil Diwan, Ph.D., President and Executive Chairman of the Company, stated, “We believe these clinical trials are an important milestone not only for NanoViricides and Karveer Meditech, India, but also for the advancement of treatments against all viral infections worldwide.” He continued, “NV-CoV-2 is aimed at satisfying the as-yet-unmet medical need of a highly effective broad-spectrum, anti-coronavirus drug that can be used for all patient populations.” In addition, it introduces a novel platform technology for the development of highly effective antiviral medications into the clinical setting.